Gesche Wieser

Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men

W. Schultze‐Seemann, P. Meyer, W. Weber, 2014, Theranostics.

Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT

V. Drendel, C. Jilg, W. Schultze‐Seemann, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer

C. Jilg, H. Rischke, W. Schultze‐Seemann, 2014, Radiation oncology.

Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.

W. Vach, S. Reske, V. Drendel, 2014, The Journal of urology.

Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only

V. Drendel, C. Jilg, H. Rischke, 2015, Strahlentherapie und Onkologie.

68Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison

C. Zamboglou, V. Drendel, C. Jilg, 2016, Theranostics.

MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer

M. Bock, M. Langer, C. Zamboglou, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivo

W. Vach, C. Jilg, H. Rischke, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences

W. Schultze‐Seemann, P. Meyer, A. Grosu, 2014 .